Adverse effects of low dose methotrexate in rheumatoid arthritis patients

Journal of the College of Physicians and Surgeons Pakistan

Volumn 22, Issue 2, 2012, Pages 101-104

  Gilani, Syed Tanveer Abbas ^a   Khan, Dilshad Ahmed ^a   Khan, Farooq Ahmad ^a   Ahmed, Mushtaq ^b  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

^b MILITARY HOSPITAL   (Pakistan)

Author keywords

Methotrexate; Minimum toxic concentration; Rheumatoid Arthritis; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; METHOTREXATE; ANTIRHEUMATIC AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYZER; ANEMIA; ARTICLE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OBSERVATIONAL STUDY; PANCYTOPENIA; PREDICTIVE VALUE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT DURATION; ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; BLOOD; BLOOD ANALYSIS; BLOOD CELL COUNT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG TOXICITY; HOSPITALIZATION; INCIDENCE; LIVER; METABOLISM; MIDDLE AGED; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEX RATIO;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; LEUKOPENIA; LIVER; MALE; METHOTREXATE; MIDDLE AGED; PANCYTOPENIA; PROGNOSIS; RISK ASSESSMENT; ROC CURVE; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84862597742     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Salliot C, Van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68:1100-4.
2. Visser K, Van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2009; 68:1094-9.
3. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66:34-45.
4. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of non-biologic and biologic diseasemodifying anti-rheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762-4.
5. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006; 58:473-92.
6. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57:163-72.
7. David E, Gerber, Stuart A, Grossman, Bathelor T, Xiaobu YE. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. Cancer Chemother Pharmacol 2007; 59:817-23.
8. Zargar M, Razi T, Barati M. Comparison of single and multidose of methotrexate in medical treatment of ectopic pregnancy. Pak J Med Sci 2008; 24:586-9.
9. Uraz S, Tahan V, Aygun C, Eren F, Unluguzel G, Yuksel M, et al. Role of ursodeoxycholic acid in prevention of methotrexateinduced liver toxicity. Dig Dis Sci 2008; 53:1071-7.
10. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68:1086-93.
11. Buhroo AM, Baba AN. Adverse effects of low dose methotrexate in patients with rheumatoid arthritis. Indian J Physical Med Rehabil 2006; 17:21-5.
12. Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005; 92:480-7.
13. Sokka T, Envalds M, Pincus T. Treatment of rheumatoid arthritis: a global perspective on the use of anti-rheumatic drugs. Mod Rheumatol 2008; 18:228-39.
14. Lebbe C, Beyeler CH, Gerber NJ, Reichen J. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994; 53:475-7.
15. Chladek J, Simkova M, Vaneckova J, Hroch M, Chladkova J, Martinkova J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64:347-55.
16. Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, et al. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 2006; 58:626-33.
17. Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheum 1996; 15:163-7.
18. Edelman J, Russel AS, Biggs DE. Methotrexate levels: a guide of therapy. Clin Exp Rheum 1983; 1:153-6.
19. MacKinnon SK, Starkebaum G, Willkens R. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1985; 15:119-26.
20. Oguey D, Kolliker F, Gerber NJ, Reichen J. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35:611-4.